Simultaneous vaccination with Prevenar and multicomponent vaccines for children: Interference or no interference?

Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP-T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants

“…6 For the remaining antigens and their associated surrogate thresholds of seroprotection (and seroconversion for PT and FHA, there being no accepted correlate of seroprotection for these antigens), the immune response was generally high and similar for the two groups, and again these responses were comparable to historical data. 7,15,25 Some descriptive differences, however, were noted between groups. Notably, the anti-PRP response was higher for the investigational vaccine in terms of the percentage of participants with a titer !1.0 mg/ml; this effect is reflected in the higher anti-PRP GMC for the investigational vaccine group.…”

“…It has previously been reported by some authors that the immunogenicity of the Hep B and PRP-T components in some multivalent combination vaccines may be influenced by concomitant administration of pneumococcal vaccine. 15,16 We therefore focused our statistical analysis on the performance of these two components. In addition, as the Hep B antigen is the new component of our hexavalent vaccine, we included the assessment of its immunogenicity as a primary objective of this study.…”

CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model

“…CFA and other strong adjuvants may override the immunomodulatory effects of the CEL-2000 if given too close together. Alternatively, the cytokine, dendritic cell, T cell and antibody responses to the initial immunization may interfere with the actions of the therapeutic CEL-2000 vaccination if therapy is given during the induction phase [52][53][54][55][56][57][58][59][60][61][62]. In human disease, CEL-2000 treatment would be proposed to be administered during the chronic phase of disease to modulate the Th17 mediated inflammatory processes responsible for tissue damage.…”

Immunogenicity of a hexavalent vaccine co-administered with 7-valent pneumococcal conjugate vaccine. Findings from the National Immunisation Programme in the Netherlands

“…Abbreviations: IH, infanrix hexa; GMC, geometric mean concentration; HBV, hepatitis B virus; FHA, filamentous hemagglutinin; D, diphtheria; T, tetanus; Pa, acellular pertussis; IPV, poliomyelitis; Hib, Haemophilus influenzae type b; EMEA, european medicines agency of potential antigenic interaction is advocated as new vaccines are introduced into national immunization programs. 3,4 The hexavalent vaccine, Infanrix hexa (GSK), was introduced into the national childhood vaccination schedule in the Netherlands on June 1, 2006 for children born to hepatitis B infected mothers and children of whom either parent was born in middle-or high-endemic countries for hepatitis B (prevalence ≥ 2%). This corresponds to approximately 18% of the total birth cohort in the Netherlands.…”

“…1,2 However, the composition of combination vaccines has become increasingly complex and concerns have been expressed that co-administration of multicomponent and mono-multivalent vaccines may lead to a suboptimal induced immune response. 3 Reduced clinical efficacy was shown in the UK with the Hemophilus influenzae type b (Hib) component when given in a combined, acellular pertussis containing vaccine (DTaP-Hib), 4…”